Close
Smartlab Europe
Inizio Ignite

News

In-Vitro Biology Capabilities Expanded By Piramal Pharma

Piramal Pharma Solutions has confirmed that it has put in a multi-million dollar investment to create a top-notch screening facility that will elevate the in-vitro biology capabilities of its drug discovery service site at Ahmedabad in India. The new expansion...

Ascletis expands production of ritonavir oral tablets & oral direct-acting antiviral R&D pipeline to treat SARS-CoV-2 infection

Ascletis Pharma Inc. announces the expansion of the production of ritonavir oral tablets and oral direct-acting antiviral R&D pipeline for the treatment of SARS-CoV-2 infection. The company’s Covid-19 pipeline currently includes (i) ritonavir oral tablet (100 mg), an authorized...

Amyris and Immunitybio Complete Joint Venture for Next Generation Covid-19 RNA Vaccine

Amyris, Inc., a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-Market operating platform, and ImmunityBio, a clinical-stage immunotherapy company, today announced the completion of a previously announced joint venture agreement to accelerate the commercialization...

Valneva Announces Positive Lot-to-Lot Consistency Trial Results for its Single-Shot Chikungunya Vaccine Candidate

Valneva SE, a specialty vaccine company, announced positive topline results from the lot-to-lot Phase 3 trial of its single-shot chikungunya vaccine candidate, VLA1553. The VLA1553-302 trial met its primary endpoint, demonstrating that three consecutively manufactured vaccine lots elicited equivalent...

Pfizer and BioNTech Receive U.S. FDA EUA of COVID-19 Vaccine Booster for Individuals 12 Years of Age and Older

Pfizer Inc. and BioNTech SE announced that the U.S. FDA has expanded the EUA of a booster dose of the Pfizer-BioNTech COVID-19 Vaccine to include individuals 12 years of age and older. The booster dose is the same dosage...

REGENXBIO Announces Orphan Drug Designation Granted to RGX-202, a Novel Gene Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy

REGENXBIO Inc. announced the U.S. FDA granted Orphan Drug Designation for RGX-202, a potential one-time gene therapy for the treatment of Duchenne muscular dystrophy (Duchenne). RGX-202 is designed to deliver a novel, optimized microdystrophin transgene with a unique C-terminal...

EC grants marketing authorisation to GSK-Virs Xevudy for Covid-19

The European Commission (EC) has granted marketing authorisation to GlaxoSmithKline (GSK) and Vir Biotechnology’s Xevudy (sotrovimab) to treat Covid-19 in the early stage. The therapy is intended to be used to treat Covid-19-infected adult as well as and adolescent individuals...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »